Chronic Graft Versus Host Disease Clinical Trial
Official title:
Assessment of Positron Emission Tomography - Computed Tomography (PET-CT) Scanning as a Potential Biomarker to Assess Disease Activity in Chronic Graft Versus Host Disease (GvHD): A Pilot Study
Graft versus Host Disease (GvHD), in both its acute and chronic forms, is the major
intrinsic complication of allogeneic hematopoeitic stem cell transplant (allo-HSCT).
Moreover, chronic GvHD may be regarded as a "late effect" of cancer therapy, and the
severity of chronic GvHD is the chief determinant of long-term survival following allo-HSCT.
Unfortunately, the investigators understanding (and thus management) of chronic GvHD is not
optimal; a recent NIH Consensus Conference has defined inadequacies in virtually all facets
of chronic GvHD management. Notably for this study, the lack of suitable biomarkers
compromises diagnosis, staging and therapeutic response evaluation of chronic GvHD - and
also hinders better understanding of the biology of this process.
In particular, the activity of chronic GvHD is often difficult to discern, potentially
causing either undertreatment, with the risk of morbidity and/or mortality due to
uncontrolled chronic GvHD, or possibly overtreatment, with potent ISTs causing unnecessary
toxicity. Obviously, the development of reliable biomarkers of chronic GvHD activity would
be a very useful advance in addressing this problem, as well as other facets of management
not addressed due to certain limitations, as detailed herein.
Potentially, certain imaging technologies could address this problem. To date, imaging
technology has been used only sporadically in chronic GvHD and is not an integral part of
routine assessments. However, and despite its nonspecific nature, certain "inflammatory"
features of some chronic GvHD cases, plus clinical similarity to certain autoimmune diseases
in which functional imaging has been tested in research trials - (and perhaps notably), a
limited experience in acute GvHD - the investigators postulate that Positron emission
tomography - computed tomography (PET-CT) scans may be useful as a biomarker of disease
activity in chronic GvHD. This protocol is an initial effort to that end.
n/a
Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Enrolling by invitation |
NCT01804686 -
A Long-term Extension Study of PCI-32765 (Ibrutinib)
|
Phase 3 | |
| Terminated |
NCT02337517 -
Vismodegib in Treating Patients With Steroid-Refractory Chronic Graft-Versus-Host Disease
|
Phase 2 | |
| Terminated |
NCT02461134 -
Clinical Study to Investigate the Biological Activity, Safety, Tolerability, and Pharmacokinetics of Ponesimod in Subjects With Symptomatic Chronic GVHD
|
Phase 2 | |
| Recruiting |
NCT03839069 -
Minor Salivary Gland Transplantation for Cicatrizing Conjunctivitis
|
N/A | |
| Active, not recruiting |
NCT00637689 -
Improving Outcomes Assessment in Chronic GVHD
|
||
| Active, not recruiting |
NCT01937468 -
Trial of Regulatory T-cells Plus Low-Dose Interleukin-2 for Steroid-Refractory Chronic Graft-versus-Host-Disease
|
Phase 1 | |
| Completed |
NCT01810718 -
Phase I/II for Safety and Efficacy of Nilotinib in a Population Steroid-refractory/or Steroid-dependent cGVHD
|
Phase 1 | |
| Completed |
NCT01380535 -
Extracorporeal Photopheresis (ECP) With Methoxsalen for Chronic Graft Versus Host Disease (cGVHD)
|
Early Phase 1 | |
| Active, not recruiting |
NCT03790332 -
Phase 1/2 Dose Finding and Safety Study of Ibrutinib in Pediatric Subjects With Chronic Graft Versus Host Disease (cGVHD)
|
Phase 1/Phase 2 | |
| Completed |
NCT01680965 -
Ofatumumab as Primary Therapy of Chronic Graft Versus Host Disease
|
Phase 1/Phase 2 | |
| Completed |
NCT02491359 -
Carfilzomib in Treating Patients With Chronic Graft-Versus-Host Disease
|
Phase 2 | |
| Terminated |
NCT02701634 -
Efficacy and Tolerability of Entospletinib in Combination With Systemic Corticosteroids as First-Line Therapy in Adults With Chronic Graft Versus Host Disease (cGVHD)
|
Phase 2 | |
| Recruiting |
NCT05567406 -
Safety and Efficacy of Oral Belumosudil in Black or African American, American Indian or Alaska Native, and Native Hawaiian or Other Pacific Islander Male and Female Participants Aged 12 Years and Above With Chronic Graft Versus Host Disease (cGVHD) After At Least 2 Prior Lines of Systemic Therapy
|
Phase 2 | |
| Active, not recruiting |
NCT04212416 -
Leflunomide in Treating Patients With Steroid Dependent Chronic Graft Versus Host Disease
|
Phase 1 | |
| Completed |
NCT02959944 -
Ibrutinib in Combination With Corticosteroids vs Placebo in Combination With Corticosteroids in Participants With New Onset Chronic Graft Versus Host Disease (cGVHD)
|
Phase 3 | |
| Not yet recruiting |
NCT06271616 -
Ibrutinib for the Prevention of Chronic Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplant
|
Phase 2 | |
| Completed |
NCT01954979 -
Abatacept to Treat Steroid Refractory Chronic Graft Versus Host Disease (cGVHD)
|
Phase 1 | |
| Active, not recruiting |
NCT04640025 -
A Rollover Study to Provide Continued Treatment for Participants Previously Enrolled in Studies of Itacitinib
|
Phase 2 | |
| Completed |
NCT03483675 -
Discontinuation or Continuation of Immunosuppressive Therapy in Participants With Chronic Graft Versus Host Disease
|
Phase 2 | |
| Recruiting |
NCT04431479 -
Predicting the Quality of Response to Specific Treatments in Patients With cGVHD, PQRST Study
|